Last updated: February 16, 2026
Overview
NDC 00597-0260 is identified as Firdapse (amifampridine) 10 mg tablets, produced by Catalyst Pharmaceuticals. It is approved for treating Lambert-Eaton myasthenic syndrome (LEMS). The drug gained FDA approval in 2018 after regulatory challenges, with a notable impact on the rare disease market.
Market Size and Demand Drivers
Patient Population
LEMS is a rare autoimmune disorder affecting approximately 3.4 per million people globally. The U.S. prevalence is estimated at 1,000 to 1,500 patients, with about 250 to 400 receiving Firdapse.
Market Penetration
As of 2023, Catalyst estimates that roughly 90% of diagnosed patients are on Firdapse, reflecting strong prescribing habits but leaving room for growth as diagnosis rates improve.
Competitive Landscape
No direct FDA-approved alternatives for LEMS exist currently. Off-label treatments include 3,4-diaminopyridine (compound with no FDA approval as a drug product), constraining competitor influence.
Pricing and Revenue Analysis
Average Wholesale Price (AWP)
The AWP for a 30-count, 10 mg Firdapse tablet is approximately $70, based on retail pharmacy data and wholesale acquisition cost (WAC) sources. Patient out-of-pocket costs vary due to insurance coverage but typically range between $5 to $20 per tablet due to co-pays and assistance programs.
Annual Revenue Estimates
Assuming 300 patients on therapy, with an average dose of one tablet daily:
| Parameter |
Value |
| Patients actively treated |
300 |
| Daily dose per patient |
1 tablet |
| Annual tablets per patient |
365 |
| Price per tablet |
$70 |
| Gross annual revenue |
$7,665,000 (300 x 365 x $70) |
Adjustments for discounts, rebates, and assistance programs (which reduce net revenue by an estimated 20-30%) suggest net revenues could be around $5.4 million annually at current market penetration levels.
Market Expansion Potential
If diagnosis rates increase and market penetration reaches 100%, revenues could surpass $8 million annually. Growth depends on increased awareness, improved diagnostics, and possible label expansions.
Price Projection Outlook
Short-term (Next 1-2 Years)
Given current demand and limited competition, pricing for Firdapse is expected to stay stable with minor fluctuations due to inflationary pressures and supply chain factors. The price per tablet likely remains in the $70-$75 range.
Medium-term (2-5 Years)
The introduction of generic versions could pressure retail prices downward by 15-25%, potentially reducing the average price to around $55-$60 per tablet. However, patent exclusivity until 2030 supports current pricing.
Long-term (Beyond 5 Years)
Patent exclusivity and market share stabilization suggest prices could plateau or slightly decline as generic entry occurs. Price decreases of 20-30% are probable, depending on exclusivity extension negotiations and generic development timelines.
Regulatory and Policy Impact
Price Regulation and Reimbursement
U.S. reform proposals targeting drug pricing transparency and inflation cap policies could influence future pricing strategies. Medicaid and Medicare discounts could further impact net pricing, adding complexity to revenue forecasts.
Market Access
Reimbursement trends favor specialty drugs like Firdapse, with payers increasingly covering orphan drugs to promote access. These trends support sustained demand at current price levels.
Competitive and Market Trends
- Lack of FDA-approved competitors limits immediate downward price pressure.
- Off-label use of 3,4-diaminopyridine remains unregulated but less lucrative for providers due to insurance coding complexities.
- Catalyst's promotional efforts and patient assistance programs influence market share and revenue stability.
Summary
| Aspect |
Detail |
| Current Market Size |
Approximately $5-8 million in annual net revenue |
| Price per Tablet |
Around $70, stable short-term, potential decrease with generics |
| Future Pricing |
Stabilizes with patent protection; declines expected post-generic entry |
| Market Drivers |
Rare disease prevalence, approval exclusivity, lack of direct competition |
| Growth Potential |
Moderate, dependent on diagnosis rates and market penetration |
Key Takeaways
- NDC 00597-0260 (Firdapse) commands a high price due to orphan status and lack of direct competitors.
- Revenue projections annualize around $5-8 million, with moderate growth potential.
- Price pressure from generics expected post-2030 could lead to a 20-30% reduction.
- Market access dynamics favor sustained demand, supported by reimbursement policies.
- Expansion relies on increased diagnosis and awareness efforts.
FAQs
1. What is the patent status for Firdapse (NDC 00597-0260)?
The primary patent protected Firdapse until 2030, supporting current pricing. Extensions or litigation could alter this timeline.
2. How does the entry of generics impact pricing?
Generic competitors could reduce prices by 15-25%, significantly affecting revenue, assuming market share shifts as expected.
3. Are there regulatory pathways to expand Firdapse’s approved indications?
Yes, but expansion depends on clinical trial data and FDA approval processes, potentially increasing market size.
4. What factors influence patient out-of-pocket costs?
Insurance coverage, copay assistance programs, and formulary placement determine patient costs, which are currently manageable.
5. How might policy changes affect the orphan drug market?
Potential reforms on drug pricing transparency and inflation caps could pressure prices but also increase access and utilization.
References
- Catalyst Pharmaceuticals. (2023). Firdapse prescribing information.
- FDA. (2018). Approval memo for Firdapse.
- IQVIA. (2023). U.S. prescription drug market data.
- Orphan Drug Designations. (2023). FDA.
- Industry analysis reports. (2023). Rare disease therapeutic market.
